Home

Some plaque psoriasis patients may need a treatment plan that calls for Amevive. Amevive is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.

Amevive may be an option for some patients. This site will help you learn more about Amevive and its established safety profile, dual MOA, efficacy, and dosing/administration.

Amevive Support Services are available to give you reimbursement information. There are also practice management support services available in this section, and further information on how to get your patients started with treatment on Amevive.

Amevive Support Services can provide you with reimbursement and other relevant information to support your practice More

Learn about the support available for physicians who prescribe Amevive

Amevive may be an option for some patients

Learn about patients Amevive may be appropriate for More

Amevive offers an established safety profile

Learn about the safety profile of Amevive More

Amevive provides extended breaks from treatment

Learn about the dosing and administration of Amevive More

Safety Considerations

Amevive should not be administered to patients infected with HIV, with a history of systemic malignancy, clinically important infection, known hypersensitivity to Amevive or any of its components, or to patients receiving other immunosuppressive agents or phototherapy.

The most serious adverse reactions in clinical trials were lymphopenia, malignancies, serious infections requiring hospitalization, and hypersensitivity reactions.

Caution should be exercised when considering the use of Amevive in patients with chronic infection, history of recurrent infection, or at high risk of malignancy. Patients should be monitored for signs and symptoms of infection during or after a course of Amevive. New infections should be closely monitored.